Azam Azeem, Klisic Aleksandra, Mercantepe Filiz, Faseeh Hamza, Mercantepe Tolga, Rafaqat Saira
Institute of Zoology, University of the Punjab, Lahore 54590, Pakistan.
Faculty of Medicine, University of Montenegro, 81000 Podgorica, Montenegro.
Life (Basel). 2024 Dec 30;15(1):34. doi: 10.3390/life15010034.
Hepatocyte carcinoma (HCC) is a globally prevalent neoplasm with profound effects on morbidity and mortality rates. This review summarizes the complex interactions between coagulation abnormalities and the pathophysiological mechanisms underlying HCC. Essential coagulation biomarkers, such as P-selectin, thrombomodulin, d-dimer, prothrombin, and von Willebrand factor, are reviewed for their diagnostic, prognostic, and therapeutic significance. The contribution of these biomarkers to tumor progression, metastatic spread, and patient prognosis is highlighted through a synthesis of contemporary research findings. In addition, this review highlights the underlying mechanisms linking coagulation pathways to HCC pathogenesis and explores potential therapeutic targets. An integrative perspective on the role of coagulation markers in HCC may improve clinical management strategies for patients affected by this malignancy.
肝细胞癌（HCC）是一种在全球范围内普遍存在的肿瘤，对发病率和死亡率有深远影响。本综述总结了凝血异常与HCC潜在病理生理机制之间的复杂相互作用。对诸如P-选择素、血栓调节蛋白、D-二聚体、凝血酶原和血管性血友病因子等重要凝血生物标志物的诊断、预后和治疗意义进行了综述。通过综合当代研究结果，突出了这些生物标志物对肿瘤进展、转移扩散和患者预后的贡献。此外，本综述强调了将凝血途径与HCC发病机制联系起来的潜在机制，并探索了潜在的治疗靶点。对凝血标志物在HCC中的作用进行综合考量，可能会改善受这种恶性肿瘤影响患者的临床管理策略。
